Giant axonal neuropathy: An updated perspective on its pathology and pathogenesis
- PMID: 24947478
- DOI: 10.1002/mus.24321
Giant axonal neuropathy: An updated perspective on its pathology and pathogenesis
Abstract
Giant axonal neuropathy (GAN) is a rare pediatric neurodegenerative disease. It is best known for the "giant" axons caused by accumulations of intermediate filaments. The disease is progressive, with onset around age 3 years and death by the third decade of life. GAN results from recessive mutations in the GAN gene encoding gigaxonin, and our analysis of all reported mutations shows that they are distributed throughout the protein structure. Precisely how these mutations cause the disease remains to be determined. In addition to changes in peripheral nerves that are similar to those seen in neuropathies such as Charcot-Marie-Tooth type 2, GAN patients exhibit a wide range of central nervous system signs. These features, corroborated by degeneration of central tracts apparent from postmortem pathology, indicate that GAN is also a progressive neurodegenerative disease. To reflect this phenotype more precisely, we therefore propose that the disease should be more appropriately referred to as "giant axonal neurodegeneration."
Keywords: giant axonal neuropathy; gigaxonin; intermediate filaments; neurodegeneration; sensorimotor neuropathy.
Copyright © 2014 Wiley Periodicals, Inc.
Similar articles
-
Giant axonal neuropathy caused by a novel compound heterozygous mutation in the gigaxonin gene.J Child Neurol. 2013 Oct;28(10):1316-9. doi: 10.1177/0883073812467688. Epub 2012 Dec 17. J Child Neurol. 2013. PMID: 23248352
-
Giant axonal neuropathy.Handb Clin Neurol. 2013;115:933-8. doi: 10.1016/B978-0-444-52902-2.00052-7. Handb Clin Neurol. 2013. PMID: 23931822 Review.
-
Clinicogenetical features of a Japanese patient with giant axonal neuropathy.Brain Dev. 2012 Feb;34(2):156-62. doi: 10.1016/j.braindev.2011.02.003. Epub 2011 Feb 26. Brain Dev. 2012. PMID: 21356581
-
The instability of the BTB-KELCH protein Gigaxonin causes Giant Axonal Neuropathy and constitutes a new penetrant and specific diagnostic test.Acta Neuropathol Commun. 2014 Apr 24;2:47. doi: 10.1186/2051-5960-2-47. Acta Neuropathol Commun. 2014. PMID: 24758703 Free PMC article.
-
Two novel mutations in the GAN gene causing giant axonal neuropathy.World J Pediatr. 2018 Jun;14(3):298-304. doi: 10.1007/s12519-018-0140-z. Epub 2018 Jun 6. World J Pediatr. 2018. PMID: 29876741 Review.
Cited by
-
Genetic Approaches for the Treatment of Giant Axonal Neuropathy.J Pers Med. 2022 Dec 30;13(1):91. doi: 10.3390/jpm13010091. J Pers Med. 2022. PMID: 36675752 Free PMC article. Review.
-
Advances in AAV-mediated gene replacement therapy for pediatric monogenic neurological disorders.Mol Ther Methods Clin Dev. 2024 Oct 16;32(4):101357. doi: 10.1016/j.omtm.2024.101357. eCollection 2024 Dec 12. Mol Ther Methods Clin Dev. 2024. PMID: 39559557 Free PMC article. Review.
-
Intermediate filament dysregulation in astrocytes in the human disease model of KLHL16 mutation in giant axonal neuropathy (GAN).Mol Biol Cell. 2023 Sep 6;34(12):mbcE23030094. doi: 10.1091/mbc.E23-03-0094. Online ahead of print. Mol Biol Cell. 2023. PMID: 37672338 Free PMC article.
-
Gigaxonin glycosylation regulates intermediate filament turnover and may impact giant axonal neuropathy etiology or treatment.JCI Insight. 2019 Nov 26;5(1):e127751. doi: 10.1172/jci.insight.127751. Print 2020 Jan 16. JCI Insight. 2019. PMID: 31944090 Free PMC article.
-
An overview of early-onset cerebellar ataxia: a practical guideline.Acta Neurol Belg. 2024 Dec;124(6):1791-1804. doi: 10.1007/s13760-024-02595-w. Epub 2024 Jul 1. Acta Neurol Belg. 2024. PMID: 38951452 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical